FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS �
Go back to FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS �| Merck & Co. (NYSE: MRK) | Delayed: 146.87 -0.28 (0.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $147.15 | 52 Week High | $65.46 | |||
| Open | $147.08 | 52 Week Low | $47.97 | |||
| Day High | $147.84 | P/E | 99.91 | |||
| Day Low | $145.74 | EPS | $1.47 | |||
| Volume | 31,159,364 | |||||
